Center for Bacterial Pathogenesis, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Department of Microbiology, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts, USA.
Microb Biotechnol. 2024 Nov;17(11):e70057. doi: 10.1111/1751-7915.70057.
Live biotherapeutic products (LBPs), including engineered bacteria, are rapidly emerging as potential therapeutic interventions. These innovative therapies can serve as live in situ drug delivery platforms for the direct deposition of therapeutic payloads, including complex biologics, at sites of disease. This approach offers a platform likely to enhance therapeutic efficacy and decrease off-target side effects. LBPs also can likely be distributed at a relatively low price point, as their production can be economically scaled up. LBPs represent an exciting new means for ensuring healthy lives and promoting well-being for all ages, aligning with the World Health Organization's sustainable development goal 3.
活菌治疗产品（LBPs），包括工程菌，正在迅速成为有潜力的治疗干预手段。这些创新疗法可以作为活的原位药物输送平台，直接将治疗有效成分（包括复杂的生物制剂）递送到疾病部位。这种方法有可能提高治疗效果，减少脱靶副作用。LBPs 的生产成本可以经济地上规模，因此也有可能以相对较低的价格点进行分销。LBPs 代表了一种确保全年龄段人群健康生活和促进健康福祉的令人兴奋的新手段，符合世界卫生组织可持续发展目标 3。
